Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization

World Journal of Gastroenterology

Volumn 11, Issue 24, 2005, Pages 3803-3805

  Guan, Yong Song ^a   Liu, Yuan ^a   Sun, Long ^a   Li, Xiao ^a   He, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chemoembolization; Hepatocellular carcinoma; p53 gene; Transcatheter arterial

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GENDICINE; IODINATED POPPYSEED OIL; PROTEIN P53;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CASE REPORT; CHEMOEMBOLIZATION; DRUG FEVER; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER NODULE; LIVER RESECTION; MALE; POSTOPERATIVE PERIOD; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE;

EID: 23844490132     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i24.3803     Document Type: Article

References (14)

1. Chen XM, Luo PF, Lin HH, Zhou ZJ, Shao PJ, Fu L, Li WK. Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma. Aizheng 2004; 23: 829-832
2. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
3. Mizoe A, Yamaguchi J, Azuma T, Fujioka H, Furui J, Kanematsu T. Transcatheter arterial embolization for advanced hepatocellular carcinoma resulting in a curative resection: report of two cases. Hepatogastroenterology 2000; 47: 1706-1710
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442
5. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: 319-328
6. Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am 2003; 12: 105-126
7. Kouraklis G. Progress in cancer gene therapy. Acta Oncol 1999; 38: 675-683
8. Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70(6 Suppl): 1810-1817
9. Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S, Wang NJ, Tabor E. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep 2000; 7: 353-356
10. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810
11. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 1995; 14: 275-285
12. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-1376
13. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law Dj, Li YG, Lau WY, Li AK. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003; 162: 1823-1829
14. Jeng KS, Sheen IS, Chen BF, Wu JY. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 2000; 135: 1329-1333